Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROSETTA Gastric-204: Pumitamig + Chemotherapy vs Nivolumab + Chemotherapy in Advanced Gastric/Esophageal Cancers
NCT07221149Phase 3Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2026
- Primary completion
- Nov 2030
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of pumitamig in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, esophageal adenocarcinoma (EAC), sponsored by Bristol Myers Squibb. Started Mar 2026; status: recruiting.
02
Drugs
pumitamig
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on NCT07221149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07221149.